A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report

Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive fatal tumor. Most ATC patients using traditional surgery or radio-chemotherapy have poor prognosis and experience recurrence in a very short time. There is no optimal therapy for ATC, and the median survival time is about 5 months. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Gui, Lin, Liu, Shaoyan, Zhang, Ye, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068508/
https://www.ncbi.nlm.nih.gov/pubmed/33907417
http://dx.doi.org/10.2147/OTT.S305196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068508/
https://www.ncbi.nlm.nih.gov/pubmed/33907417
http://dx.doi.org/10.2147/OTT.S305196

Ejemplares similares